|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1800016117 |
|
最近更新日期: Date of Last Refreshed on: |
2019-01-15 17:57:01 |
|
注册时间: Date of Registration: |
2018-05-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中医药治疗原发性肝癌:一项基于真实世界的回顾性队列研究 |
|
Public title: |
Treatment of primary liver cancer with traditional Chinese medicine: a retrospective cohort study based on the real world |
|
注册题目简写: |
中医药治疗原发性肝癌真实世界研究 |
|
English Acronym: |
A real-world study on the treatment of primary liver cancer with traditional Chinese medicine |
|
研究课题的正式科学名称: |
基于真实世界中医临床数据的原发性肝癌循证证据构建研究 |
|
Scientific title: |
Study of constructing evidence-based evidence of primary carcinoma of the liver based on real-world clinical data of TCM |
|
研究课题代号(代码): Study subject ID: |
H2721 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张强 |
研究负责人: |
邵明义 |
|
Applicant: |
Zhang Qiang |
Study leader: |
Shao Mingyi |
|
申请注册联系人电话: Applicant telephone: |
+86 17837178672 |
研究负责人电话: Study leader's telephone: |
+86 13523710661 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangqiangq7@126.com |
研究负责人电子邮件: Study leader's E-mail: |
shmy1016@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市金水东路156号 |
研究负责人通讯地址: |
河南省郑州市人民路19号 |
|
Applicant address: |
156 Jinshui Road East, Zhengzhou, He'nan, China |
Study leader's address: |
19 Renmin Road, Zhengzhou, He'nan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
450046 |
研究负责人邮政编码: Study leader's postcode: |
450000 |
|
申请人所在单位: |
河南中医药大学 |
||
|
Applicant's institution: |
Henan University of Chinese Medicine |
||
|
研究负责人所在单位: |
河南中医药大学第一附属医院 |
||
|
Affiliation of the Leader: |
The first affiliated Hospital of Henan University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2017HL-077 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河南中医药大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the first affiliated Hospital of He'nan University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2017-10-27 00:00:00 |
||
|
伦理委员会联系人: |
王春芳 |
||
|
Contact Name of the ethic committee: |
Wang Chunfang |
||
|
伦理委员会联系地址: |
河南省郑州市人民路19号 |
||
|
Contact Address of the ethic committee: |
19 Renmin Road, Zhengzhou, He'nan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 0371-66285929 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河南中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The first affiliated Hospital of He'nan University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省郑州市人民路19号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
19 Renmin Road, Zhengzhou, He'nan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation. |
||||||||||||||||||||||
|
Target disease: |
primary carcinoma of liver |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
基于真实世界临床数据评价中医药治疗原发性肝癌的临床疗效。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the clinical efficacy of TCM in the treatment of primary liver cancer based on real world clinical data. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
通过采集2015年至2017年期间真实世界原发性肝癌治疗过程中应用中药(包括中草药和中成药)的数据, 以临床应用中药时间≥1个月定义为应用中药治疗,以临床应用中药时间<1个月定义为非应用中药治疗; |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
By collecting data on the application of traditional Chinese medicine (including Chinese herbal medicine and proprietary Chinese medicine) in the treatment of real world primary liver cancer from 2015 to 2017, The clinical application time of Chinese medicine 1 month was defined as the application of Chinese medicine therapy, and the clinical application time of Chinese medicine < 1 month was defined as the non-application of Chinese medicine therapy. |
||||||||||||||||||||||
|
纳入标准: |
符合(2015版)原发性肝癌组织病理学或影像学诊断标准患者;年龄在18周岁以上男性或女性患者;能获得完整病历信息的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients who meet the histopathological or imaging diagnostic criteria for primary liver cancer (2015 edition); Male or female patients aged 18 or above; Patients who have access to complete medical information. |
||||||||||||||||||||||
|
排除标准: |
所有原始电子病历或者纸质病历信息不完整的患者;只住院一次且住院时间小于24小时的患者;只住院一次且确诊后无法获得随访信息的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
All patients whose original electronic medical records or paper medical records are incomplete; Patients who were hospitalized once and for less than 24 hours; Patients who were unable to obtain follow-up information after diagnosis. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-10-27 00:00:00至 To 2019-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2018-05-15 00:00:00 至 To 2019-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本试验为观察性队列研究,无需产生随机序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This experiment is an observational cohort study without generating random sequences. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2019年12月31日后联系研究单位负责人shmy1016@163.com可获取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究数据全部记录纸质CRF表中,由研究单位保存管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All the research data are recorded in the paper CRF table, which is kept and managed by the research unit. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |